DAUNOXOME Drug Patent Profile
✉ Email this page to a colleague
When do Daunoxome patents expire, and what generic alternatives are available?
Daunoxome is a drug marketed by Galen (uk) and is included in one NDA.
The generic ingredient in DAUNOXOME is daunorubicin citrate. There are eleven drug master file entries for this compound. Additional details are available on the daunorubicin citrate profile page.
Summary for DAUNOXOME
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 55 |
Clinical Trials: | 12 |
Patent Applications: | 4,509 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DAUNOXOME at DailyMed |
Recent Clinical Trials for DAUNOXOME
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tara Lin | Phase 1 |
University of Kansas Medical Center | Phase 1 |
Vastra Gotaland Region | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for DAUNOXOME
US Patents and Regulatory Information for DAUNOXOME
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Galen (uk) | DAUNOXOME | daunorubicin citrate | INJECTABLE, LIPOSOMAL;INJECTION | 050704-002 | Apr 8, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |